DS BIOPHARMA ABSTRACTS ACCEPTED AT THE ATOPIC DERMATITIS CENTRE OF REFERENCE AND EXCELLENCE (ADCARE) 2021 CONFERENCE

Pipeline full with agents in various phases of development | Dermatology Times
November 19, 2019
DS Biopharma and Nuvothera Enter Option and License Agreement for EPADILIN®
March 18, 2021
Show all

DS BIOPHARMA ABSTRACTS ACCEPTED AT THE ATOPIC DERMATITIS CENTRE OF REFERENCE AND EXCELLENCE (ADCARE) 2021 CONFERENCE

DS Biopharma (DS) has successfully submitted two abstracts to the Atopic Dermatitis Centre of Reference and Excellence (ADCARE) 2021 conference.

A link to the abstract “Steroid-sparing potential of Daleuton cream in Atopic Dermatitis patients” can be found here.

A link to the abstract “EPADILIN®: Increases Skin Hydration and Improves Skin Surface Profile” can be found here.

The ADCARE Conference originally scheduled for 21st/22nd of January 2021 will now take place between the 12th and 13th of August 2021 in Berlin, Germany.